Seeking New Heights: Advancing the Standard of Care in CKD-Associated Anemia With Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitors

Curriculum Description

Anemia in chronic kidney disease (CKD) is often underdiagnosed and undertreated, although it is a common complication of CKD. Iron therapy, erythropoiesis-stimulating agents (ESAs), and red blood cell transfusions have been used to treat patients with CKD-associated anemia; however, these treatments have known limitations. Growing evidence from phase 3 trials supports hypoxia-inducible factor (HIF) via prolyl hydroxylase (PH) domain inhibition as a promising new therapeutic approach with a number of advantages over current treatment options. In this education collection, leading experts explore the pathophysiology of anemia in CKD and the clinical data supporting the use of HIF-PH inhibitors to treat patients with this condition. They also discuss how these novel agents can improve overall care and outcomes for patients with CKD.

Target Audience

These activities have been designed to meet the educational needs of nephrologists, cardiologists, internists, primary care physicians, endocrinologists, pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians involved in the care of patients with CKD-associated anemia.

Steering Committee

Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana

Javed Butler, MD, MPH, MBA
University of Mississippi Medical Center
Jackson, Mississippi

Debra J. Hain, PhD, APRN, AGPCNP-BC, FAAN, FAANP, FNKF
Florida Atlantic University
Christine E. Lynn College of Nursing
Boca Raton, Florida

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

Updates from Steering Committee

Update on the Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors - Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF

Activities

0.5 CME/MOC/NCPD/CPE
33:14
March 26, 2021

Targeting HIF Stabilization as a Treatment for Anemia in CKD

Jay B. Wish, MD

May
10
Monday - 7:00 PM EDT
Live Web Broadcast
1.25 CME/NCPD
Live Web Broadcast

HIF-PH Inhibitors for Managing Anemia in Patients With Chronic Kidney Disease

Rajiv Agarwal, MD, MS, will be joined by Steven Fishbane, MD, and Shushanne Wynter-Minott, DNP, FNP-BC, APRN, as presenters for this educational activity.

Practice Aid Point-of-Care Tools

Targeting HIF Stabilization as a Treatment for Anemia in CKD

Teaching & Learning Materials

Targeting HIF Stabilization as a Treatment for Anemia in CKD

Playlist

Targeting HIF Stabilization as a Treatment for Anemia in CKD

Jay B. Wish, MD

Subscribe to Podcasts

Providership & Support

This education collection is provided by Medical Learning Institute, Inc.

These activities are developed with our educational partner, PVI, PeerView Institute for Medical Education.

These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP in collaboration with FibroGen.